Cancer-fighting biotech startup InduPro raises $85M round
InduPro Inc., a biotechnology company dual- headquartered in Seattle and Cambridge, Massachusetts, recently announced its success in raising $85 million in Series A round funding. Founded in 2022, InduPro will utilize the funding to support and advance its cancer treatments from preclinical stages to phase 1 trial, expected to begin in Q4 of 2025.
Recently, the company appointed Prakash Raman, Ph.D. to CEO, bringing in more than two decades of biopharmaceutical business development experience. In a recent release, Raman said, “We are discovering novel targets and best-in class approaches for areas of high unmet need for many cancer and autoimmune patients.”
With this funding, InduPro’s advancements in cancer and autoimmune treatments are set to enhance an already robust healthcare industry in Seattle.